Expression of a Chimeric Allergen with High Rare Codons Content in Codon Bias-Adjusted Escherichia coli: Escherichia coli BL21 (DE3)-Codon Plus RIL as an Efficient Host

Abstract

The expression of heterologous proteins in Escherichia coli (E. coli) is importantly affected by codon bias. Hence, the aim of the current study was to determine which codon bias-adjusted E. coli strain is sufficient for expression of a chimeric allergen coded by high rare codon content. To investigate the expression level, a chimeric protein of Chenopodium album (C. album) was used as an appropriate model. An expression construct was assembled and was transformed to four strains of codon bias-adjusted E. coli including origami, BL21 (DE3), BL21 (DE3)-codon plus RIL, and Rosetta. The level of expression and solubility of the chimeric allergen was analyzed by SDS-PAGE. In addition, the allergenicity of chimeric allergen was determined using immunoblotting. Our results showed that the chimeric allergen was expressed at high level in E. coli BL21 (DE3)-codon plus RIL and Rosetta. In detail, this recombinant allergen was isolated from soluble fraction in the codon bias-adjusted strains of E. coli BL21 (DE3)-codon plus RIL and Rosetta. Moreover, some lower molecular weight proteins were observed in Rosetta, which could be related to inappropriate expression or broken compartments of the chimeric allergen. The immunoblotting assay confirmed that the IgE-specific immune reactivity of our chimeric allergen expressed in BL21 (DE3)-codon plus RIL was significantly higher than the other strains. Our results showed that the expression of the chimeric allergen with high rare codons content in a codon bias-adjusted strain E. coli BL21 (DE3)-codon plus RIL improves the quality and solubility of the heterologous protein production.

Exploiting reverse vaccinology approach for the design of a multiepitope subunit vaccine against the major SARS-CoV-2 variants

“…Therefore, it was necessary to optimize the codon for the vaccine construct according to the use of the E. coli expression system to ensure efficient translation and increased protein production Rosano and Ceccarelli (2014) . The results of codon optimization of the vaccine with a GC content of 50.73%, which is in the optimal range (30-70%), indicate good comprehensive stability of the mRNA of the synthetic gene Grote et al, 2005 , Nouri et al, 2016 . The CAI value was predicted to be 1.0, in the range (0.8-1.0) signifies the maximum codon affinity and indicates high expression of our designed vaccine constructs in E. coli K12 strain Chen (2012) .…”

Ceftazidime and Usnic Acid Encapsulated in Chitosan-Coated Liposomes for Oral Administration against Colorectal Cancer-Inducing Escherichia coli

“…Preventive treatment with the use of antibiotics against bacteria related to the development of cancer, such as those observed in Helicobacter pylori and gastric cancer, is already widely reported in the literature [ 100 ]. Considering studies such as those by Nouri et al [ 101 ], which found the presence of pKs E. coli in 23% of the CRC group compared to 7.1% in the control group, corroborating with previous research by Buc et al [ 102 ], who identified it in 39.5% of individuals with CRC and 12.9% of patients with diverticulosis, it becomes evident that the pKs island can be considered a relevant biomarker for CRC development [ 101 , 102 ]. Furthermore, given its role in colorectal cancer pathogenesis, the pKs island also emerges as a promising target for the use of antibiotics as a preventive strategy.…”